Your browser doesn't support javascript.
loading
Recombinant Adeno-Associated Virus-Mediated Expression of Methamphetamine Antibody Attenuates Methamphetamine-Induced Hyperactivity in Mice.
Chen, Yun-Hsiang; Wu, Kuo-Jen; Wu, Kuang-Lun; Wu, Kun-Lieh; Tsai, Ho-Min; Chen, Mao-Liang; Chen, Yi-Wei; Hsieh, Wei; Lin, Chun-Ming; Wang, Yun.
Afiliación
  • Chen YH; Department of Life Science, Fu-Jen Catholic University, New Taipei City, Taiwan.
  • Wu KJ; Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Taiwan.
  • Wu KL; Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Taiwan.
  • Wu KL; Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Taiwan.
  • Tsai HM; Department of Electrical Engineering of I-Shou University, Kaohsiung, Taiwan.
  • Chen ML; Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Taiwan.
  • Chen YW; Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.
  • Hsieh W; Department of Life Science, Fu-Jen Catholic University, New Taipei City, Taiwan.
  • Lin CM; Department of Life Science, Fu-Jen Catholic University, New Taipei City, Taiwan.
  • Wang Y; Department of Microbiology, Soochow University, Taipei, Taiwan.
Sci Rep ; 7: 46301, 2017 04 07.
Article en En | MEDLINE | ID: mdl-28387350
ABSTRACT
Methamphetamine (Meth) is one of the most frequently abused drugs worldwide. Recent studies have indicated that antibodies with high affinity for Meth reduce its pharmacological effects. The purpose of this study was to develop a technique for virus-based passive immunization against Meth effects. We generated a recombinant adeno-associated virus serotype-8 vector (AAV-MethAb) carrying the gene for a Meth-specific monoclonal antibody (MethAb). Infection of 293 cells with AAV-MethAb resulted in the expression and secretion of antibodies which bind to Meth. The viral vector was then examined in adult ICR mice. Systemic administration of AAV-MethAb resulted in long-term expression of MethAb in the serum for up to 29 weeks. Serum collected from the animals receiving AAV-MethAb retained a high specificity for (+)-Meth. Animals were challenged with Meth five weeks after viral injection. Meth levels in the brain and serum were reduced while Meth-induced locomotor activity was significantly attenuated. In conclusion, AAV-MethAb administration effectively depletes Meth from brain and serum while reducing the behavioral response to Meth, and thus is a potential therapeutic approach for Meth abuse.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunización Pasiva / Trastornos Relacionados con Anfetaminas / Anticuerpos Neutralizantes / Hipercinesia / Metanfetamina Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals / Humans / Male Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: Taiwán

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunización Pasiva / Trastornos Relacionados con Anfetaminas / Anticuerpos Neutralizantes / Hipercinesia / Metanfetamina Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Animals / Humans / Male Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: Taiwán